Chiba S. Notch signaling in stem cell systems. Stem Cells 2006; 24: 2437–2447.
Fre S, Huyghe M, Mourikis P, Robine S, Louvard D, Artavanis-Tsakonas S. Notch signals control the fate of immature progenitor cells in the intestine. Nature 2005; 435: 964–968.
van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H et al. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005; 435: 959–963.
Hassan KA, Wang L, Korkaya H, Chen G, Maillard I, Beer DG et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 2013; 19: 1972–1980.
Ali SA, Justilien V, Jamieson L, Murray NR, Fields AP. Protein kinase ciota drives a NOTCH3-dependent stem-like phenotype in mutant KRAS lung adenocarcinoma. Cancer Cell 2016; 29: 367–378.
Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010; 70: 709–718.
Yap LF, Lee D, Khairuddin A, Pairan MF, Puspita B, Siar CH et al. The opposing roles of NOTCH signalling in head and neck cancer: a mini review. Oral Dis 2015; 21: 850–857.
Nagamatsu I, Onishi H, Matsushita S, Kubo M, Kai M, Imaizumi A et al. NOTCH4 is a potential therapeutic target for triple-negative breast cancer. Anticancer Res 2014; 34: 69–80.
Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ et al. A microRNA miR-34a-regulated bimodal switch targets Notch in colon cancer stem cells. Cell Stem Cell 2013; 12: 602–615.
Zhou ZC, Dong QG, Fu DL, Gong YY, Ni QX. Characteristics of Notch2(+) pancreatic cancer stem-like cells and the relationship with centroacinar cells. Cell Biol Int 2013; 37: 805–811.
Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther 2013; 139: 95–110.
Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors. Clin Cancer Res 2013; 19: 1512–1524.
Chen X, Gong L, Ou R, Zheng Z, Chen J, Xie F et al. Sequential combination therapy of ovarian cancer with cisplatin and gamma-secretase inhibitor MK-0752. Gynecol Oncol 2016; 140: 537–544.
Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A et al. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010; 9: 1618–1628.
He W, Luistro L, Carvajal D, Smith M, Nevins T, Yin X et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the gamma-secretase inhibitor, RO4929097. Mol Oncol 2011; 5: 292–301.
Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614–624.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860–867.
Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramskold D, Sandberg R et al. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKalpha/IKKbeta. Oncogene 2013; 32: 4892–4902.
Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005; 65: 8530–8537.
Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19: 192–205.
Sansone P, Ceccarelli C, Berishaj M, Chang Q, Rajasekhar VK, Perna F et al. Self-renewal of CD133(hi) cells by IL6/Notch3 signalling regulates endocrine resistance in metastatic breast cancer. Nat Commun 2016; 7: 10442.
Peng D, Tanikawa T, Li W, Zhao L, Vatan L, Szeliga W et al. Myeloid-derived suppressor cells endow stem-like qualities to breast cancer cells through IL6/STAT3 and NO/NOTCH cross-talk signaling. Cancer Res 2016; 76: 3156–3165.
Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene 2011; 30: 4075–4086.
Iriondo O, Rabano M, Domenici G, Carlevaris O, Lopez-Ruiz JA, Zabalza I et al. Distinct breast cancer stem/progenitor cell populations require either HIF1alpha or loss of PHD3 to expand under hypoxic conditions. Oncotarget 2015; 6: 31721–31739.
Gao P, Zhang H, Dinavahi R, Li F, Xiang Y, Raman V et al. HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell 2007; 12: 230–238.
Choy L, Hagenbeek TJ, Solon M, French D, Finkle D, Shelton A et al. Constitutive NOTCH3 signaling promotes the growth of basal breast cancers. Cancer Res 2017; 77: 1439–1452.
Romer S, Saunders U, Jack HM, Jehn BM. Notch1 enhances B-cell receptor-induced apoptosis in mature activated B cells without affecting cell cycle progression and surface IgM expression. Cell Death Differ 2003; 10: 833–844.
Benson JR, Jatoi I, Keisch M, Esteva FJ, Makris A, Jordan VC. Early breast cancer. Lancet 2009; 373: 1463–1479.
Debeb BG, Cohen EN, Boley K, Freiter EM, Li L, Robertson FM et al. Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells. Breast Cancer Res Treat 2012; 134: 495–510.
Cui H, Kong Y, Xu M, Zhang H. Notch3 functions as a tumor suppressor by controlling cellular senescence. Cancer Res 2013; 73: 3451–3459.
Dienz O, Eaton SM, Bond JP, Neveu W, Moquin D, Noubade R et al. The induction of antibody production by IL-6 is indirectly mediated by IL-21 produced by CD4+ T cells. J Exp Med 2009; 206: 69–78.
Youinou P, Jamin C. The weight of interleukin-6 in B cell-related autoimmune disorders. J Autoimmun 2009; 32: 206–210.
Knupfer H, Preiss R. sIL-6R: more than an agonist? Immunol Cell Biol 2008; 86: 87–91.
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Investig 2007; 117: 3988–4002.
Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene 2010; 29: 201–213.
Maier MM, Gessler M. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes. Biochem Biophys Res Commun 2000; 275: 652–660.
Gustafsson MV, Zheng X, Pereira T, Gradin K, Jin S, Lundkvist J et al. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev Cell 2005; 9: 617–628.
Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399: 271–275.
Semenza GL. Hydroxylation of HIF-1: oxygen sensing at the molecular level. Physiology 2004; 19: 176–182.
Wang Y, Liu Y, Malek SN, Zheng P, Liu Y. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011; 8: 399–411.
Sahlgren C, Gustafsson MV, Jin S, Poellinger L, Lendahl U. Notch signaling mediates hypoxia-induced tumor cell migration and invasion. Proc Natl Acad Sci USA 2008; 105: 6392–6397.
Liu S, Cong Y, Wang D, Sun Y, Deng L, Liu Y et al. Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. Stem Cell Rep 2014; 2: 78–91.